Item 2. Unregistered Sales of Equity Securities
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
(a) None.
(b) The section entitled “Use of Proceeds” from our registration statement filed on November 12, 2009, as amended (the “Registration Statement”) is incorporated herein by reference. The effective date of the Registration Statement is March 26, 2010, and the Commission file number assigned to the Registration Statement is 333-163041. The Registration Statement registered the offering of up to 1,500,000 common shares (the “Offering”). As of June 30, 2011, the Company has spent proceeds from the Offering in accordance with the following table:
Description of Use
Proposed
Expenditure
Amount
Actual Expenditures
through
June 30, 2011
Product Research and Development
$
2,650,333
$
2,383,677
Marketing
3,180,399
4,374,417
Potential Acquisitions
2,120,266
—
Working Capital
2,650,333
3,421,310
Total
$
10,601,331
$
10,179,404
Because we have not yet completed any acquisitions, our management determined that it was in the best interest of the Company to devote IPO proceeds to continue to grow our business. In particular, we exceeded our anticipated marketing expenditures by $1,194,018 and our anticipated working capital expenditures by $770,977, in part by participating in several international medical device manufacturer fairs. To the extent we are able to engage in acquisitions, we will need to rely on a variety of sources of funding, including but not limited to remaining offering proceeds, operating cash and debt and/or equity financing.
(c) None.
Item 3. Defaults upon Senior Securities
None.
Item 4. Submission of Matters to a Vote of Security Holders
None.
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.